BSP16 is a highly potent, orally active stimulator of the interferon gene (STING) agonist that selectively activates the STING pathway, induces the production of type I interferons (IFNs) and pro-inflammatory cytokines, and elicits a systemic antitumor immune response. BSP16 is intended for use in cancer research.

Methods: ISG-THP1 cells and ISG-RAW264.7 mouse macrophages were treated with BSP16 (0–30 μM) for 0–12 hours, and the mRNA expression levels of IFNβ, CXCL10, and IL-6 were detected by qPCR.
Results: BSP16 induced IFNβ, CXCL10, and IL-6 expression in a concentration- and time-dependent manner; IFNβ reached its peak at 1 hour, while CXCL10 and IL-6 reached their peaks at 6 hours. [1]

Methods: To investigate the antitumor efficacy of BSP16, female BALB/c mice were subcutaneously inoculated with CT26 cells and administered BSP16 (30 mg/kg) via oral gavage once every 3 days for 21 days.
Results: In the BSP16 (30 mg/kg) group, tumors completely regressed and there was no significant decrease in body weight. [1]
Methods: To investigate the effects of BSP16 on immune cell activation, MC38 tumor-bearing mice were administered BSP16 (30 mg/kg) via oral gavage every 3 days for 21 days, and their spleens were harvested 2 days after the end of treatment.
Results: BSP16 significantly increased the proportions of CD69⁺ CD8⁺ T cells and CD69⁺ NK cells in the spleen. [1]